
Immunome Investor Relations Material
Latest events

Investor Presentation
21 May, 2025

Q1 2025
12 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Immunome Inc
Access all reports
Immunome, Inc. is a biotechnology company focused on developing targeted cancer therapies. The company leverages a proprietary discovery platform to identify novel antigens and develop corresponding therapies, particularly in the field of oncology. Immunome's product pipeline includes several candidates, such as AL102, a gamma secretase inhibitor currently in Phase 3 trials for the treatment of desmoid tumors, and other preclinical assets aimed at targeting specific cancer markers through various therapeutic approaches, including antibody-drug conjugates (ADCs) and radioligand therapies. The company is headquartered in Bothell, Washington, and its shares are listed on the NASDAQ.
Key slides for Immunome Inc


Investor Presentation
Immunome Inc


Investor Presentation
Immunome Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
IMNM
Country
🇺🇸 United States